BioTime announced the expansion of its ongoing phase 1/2a clinical trial for OpRegen, with the addition of two new U.S. sites that are expected to begin treating patients later this quarter.
“The addition of these two leading U.S. clinical trial sites is in addition to our current two sites in California. We are actively recruiting patients and are in line with our plans to meet our patient enrollment projections over the next few months,” Dr. Gary S. Hogge, Senior Vice President of Clinical and Medical Affairs of BioTime, said in a company news release. “We are pleased to be working with two more leading U.S. clinicians in ophthalmology, Dr. Diana V. Do and Dr. David Telander, and their respective institutions. We are excited with the increased interest in OpRegen from both physicians and patients and remain on track with our Cohort 4 enrollment and treatment plans.”
Dr. Do is a board-certified ophthalmologist and is an expert in the management of age related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinal detachment, macular hole, retinal infections, and epiretinal membranes. Dr. Do is a leading clinician-scientist who has authored over 150 publications in medical literature and has contributed to over 25 book chapters. She has been the principal investigator and co-investigator on more than 45 clinical trials investigating novel treatments for retinal diseases and ocular inflammation.
Dr. Telander is a board-certified ophthalmologist. He received his BAS at Stanford, and completed his MD and PhD at the University of Minnesota. Dr. Telander received his surgical retina fellowship training at the UCLA Jules Stein Eye Institute in Los Angeles. He joined UC Davis in Sacramento in 2005, where he became an Associate Professor and taught residents and fellows. Dr. Telander joined Retinal Consultants of Sacramento in 2012 and continues to serve as a Clinical Professor at UC Davis and Associate Professor at California Northstate University College of Medicine. He has served as principal and sub-investigator for numerous clinical trials investigating treatments for age-related macular degeneration, diabetic retinopathy, and inherited retinal dystrophies. Dr. Telander has authored over 50 papers, many book chapters and has given national and international talks on retinal disease. He is an active member of multiple professional societies including the Retina Society, the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the American Society of Retina Specialists. Dr. Telander received the Achievement Award from the American Academy of Ophthalmology for his service.